Share on StockTwits
 

Stock analysts at Roth Capital raised their target price on shares of Pharmacyclics (NASDAQ:PCYC) to $166.00 in a report issued on Thursday, StockRatingsNetwork reports. Roth Capital’s price objective would suggest a potential upside of 25.75% from the company’s current price.

Other equities research analysts have also recently issued reports about the stock. Analysts at Zacks reiterated a “neutral” rating on shares of Pharmacyclics in a research note on Monday, January 27th. They now have a $142.00 price target on the stock. Separately, analysts at Nomura initiated coverage on shares of Pharmacyclics in a research note on Wednesday, January 8th. They set a “buy” rating on the stock. Finally, analysts at WallachBeth Capital initiated coverage on shares of Pharmacyclics in a research note on Wednesday, December 18th. They set a “hold” rating and a $108.00 price target on the stock. Five equities research analysts have rated the stock with a hold rating and eleven have assigned a buy rating to the company’s stock. The company presently has an average rating of “Buy” and an average target price of $143.81.

Shares of Pharmacyclics (NASDAQ:PCYC) traded up 1.65% during mid-day trading on Thursday, hitting $139.255. 716,712 shares of the company’s stock traded hands. Pharmacyclics has a 1-year low of $71.85 and a 1-year high of $145.30. The stock’s 50-day moving average is $127.4 and its 200-day moving average is $121.5. The company has a market cap of $10.265 billion and a P/E ratio of 231.81.

Pharmacyclics, Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing small-molecule drugs for the treatment of cancer and immune mediated diseases.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.